Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Fig. 2

Hazard ratios* for malignancies in abatacept versus other b/tsDMARD Initiators: a) total malignancy, b) lung cancer, c) lymphoma, d) breast cancer, e) non-melanoma skin cancer. *Error bars represent 95% CIs. One ICD-9-CM code. b/tsDMARDs, biologic or targeted synthetic disease-modifying antirheumatic drugs; CI, confidence interval; HR, hazard ratio; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification

Back to article page